Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Liabilities and Shareholders Equity: 2015-2025

Historic Liabilities and Shareholders Equity for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $925.3 million.

  • Intellia Therapeutics' Liabilities and Shareholders Equity fell 21.14% to $925.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year decrease of 18.76%. This contributed to the annual value of $1.2 billion for FY2024, which is 8.45% down from last year.
  • Intellia Therapeutics' Liabilities and Shareholders Equity amounted to $925.3 million in Q3 2025, which was up 2.93% from $898.9 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Liabilities and Shareholders Equity peaked at $1.5 billion during Q4 2022, and registered a low of $672.2 million during Q2 2021.
  • Over the past 3 years, Intellia Therapeutics' median Liabilities and Shareholders Equity value was $1.2 billion (recorded in 2024), while the average stood at $1.2 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 191.12% in 2021, then decreased by 24.56% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $1.3 billion in 2021, then climbed by 17.43% to $1.5 billion in 2022, then declined by 14.42% to $1.3 billion in 2023, then dropped by 8.45% to $1.2 billion in 2024, then dropped by 21.14% to $925.3 million in 2025.
  • Its last three reported values are $925.3 million in Q3 2025, $898.9 million for Q2 2025, and $986.2 million during Q1 2025.